A Study on Biochemical response and toxicity profile in very low, and intermediate risk prostate cancer individuals after stereotactic body radiotherapy

Fuente: Zenodo
Enregistré dans:
Détails bibliographiques
Auteurs principaux: A. Kiran Kumar, Nadiminti Madhavi, B Sirisha
Format: Recurso digital
Langue:anglais
Publié: Zenodo 2024
Sujets:
Accès en ligne:
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
_version_ 1866901504223346688
author A. Kiran Kumar
Nadiminti Madhavi
B Sirisha
author_facet A. Kiran Kumar
Nadiminti Madhavi
B Sirisha
contents <p><strong>Introduction: </strong>Prostate cancer (PC) is the second most common cancer globally, with significant incidence in India. Various treatment options exist, but Stereotactic Body Radiotherapy (SBRT) is emerging as a precise method for managing very low, low, and intermediate-risk PC. This study aims to assess the efficacy and toxicity profile of SBRT in these patients. <strong>Methods:</strong> This prospective observational study at Omega Hospital, Hyderabad, involved 30 patients with localized prostate cancer treated with Stereotactic Body Radiotherapy (SBRT). Inclusion criteria included men over 18 years with a WHO performance status of 0-2. The study assessed PSA levels and toxicity profiles during and after treatment, following ethical approvals. <strong>Results:</strong> In this study, 40% of participants were under 65, 20% were over 76, and the rest were aged 66–75. Mean baseline PSA dropped significantly from 11.86 ng/dl to 0.71 ng/dl over 12 months post-SBRT. Most experienced grade 1 acute gastrointestinal and genitourinary toxicity, with no toxicity above grade 1 by three months. <strong>Conclusion: </strong>This study underscores SBRT’s effectiveness and safety in localized prostate cancer, showing significant PSA reduction and durable biochemical control. With mostly grade 1 acute gastrointestinal and genitourinary toxicity, SBRT proves to be a viable treatment option, offering effective cancer control and minimal impact on quality of life.</p>
format Recurso digital
id zenodo_https___doi_org_10_5281_zenodo_14621960
institution Zenodo
language eng
publishDate 2024
publisher Zenodo
record_format zenodo
spellingShingle A Study on Biochemical response and toxicity profile in very low, and intermediate risk prostate cancer individuals after stereotactic body radiotherapy
A. Kiran Kumar
Nadiminti Madhavi
B Sirisha
Prostate Cancer, SBRT (Stereotactic Body Radiotherapy), Biochemical Control, Toxicity Profile, Quality of Life
<p><strong>Introduction: </strong>Prostate cancer (PC) is the second most common cancer globally, with significant incidence in India. Various treatment options exist, but Stereotactic Body Radiotherapy (SBRT) is emerging as a precise method for managing very low, low, and intermediate-risk PC. This study aims to assess the efficacy and toxicity profile of SBRT in these patients. <strong>Methods:</strong> This prospective observational study at Omega Hospital, Hyderabad, involved 30 patients with localized prostate cancer treated with Stereotactic Body Radiotherapy (SBRT). Inclusion criteria included men over 18 years with a WHO performance status of 0-2. The study assessed PSA levels and toxicity profiles during and after treatment, following ethical approvals. <strong>Results:</strong> In this study, 40% of participants were under 65, 20% were over 76, and the rest were aged 66–75. Mean baseline PSA dropped significantly from 11.86 ng/dl to 0.71 ng/dl over 12 months post-SBRT. Most experienced grade 1 acute gastrointestinal and genitourinary toxicity, with no toxicity above grade 1 by three months. <strong>Conclusion: </strong>This study underscores SBRT’s effectiveness and safety in localized prostate cancer, showing significant PSA reduction and durable biochemical control. With mostly grade 1 acute gastrointestinal and genitourinary toxicity, SBRT proves to be a viable treatment option, offering effective cancer control and minimal impact on quality of life.</p>
title A Study on Biochemical response and toxicity profile in very low, and intermediate risk prostate cancer individuals after stereotactic body radiotherapy
topic Prostate Cancer, SBRT (Stereotactic Body Radiotherapy), Biochemical Control, Toxicity Profile, Quality of Life
url https://doi.org/10.5281/zenodo.14621960